Researchers at the University of Pittsburgh School of Medicine have successfully induced human insulin-producing cells, known as beta cells, to replicate robustly in a living animal, as well as in the lab. The discovery not only could improve models and methods for studying diabetes, but also opens up new possibilities for treating the condition. “Most
Full Post: Important discovery in human insulin-producing cells
A new study shows that antidepressant drugs which only affect serotonin, often used as first choice treatments, may not be best for depression in people with Parkinson’s disease.
The new research is published in the December 17, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology. Depression affects up to 50 percent of people with Parkinson’s disease.
The study is the first to compare an older antidepressant that targets two receptors in the brain with a newer generation serotonin only-based drug and placebo. It is also the largest placebo-controlled study for Parkinson’s disease depression.
In the study, scientists gave 52 people diagnosed with Parkinson’s disease and depression either nortriptyline, a tricyclic antidepressant (TCA), paroxetine CR, a selective serotonin reuptake inhibitor (SSRI) or a placebo pill. Tricyclics affect both norepinephrine and serotonin, two different receptors in the brain. The people were tested for improvement of depression symptoms at two, four and eight weeks after starting treatment.
The study found that the people who took nortriptyline were nearly five times more likely to see improvement in depression symptoms when compared with the people who took paroxetine CR.
“I think that this study shows a number of important things. First, that people with Parkinson’s disease can respond to antidepressants. This is important because depression in Parkinson’s disease is underrecognized, underappreciated and undertreated. Commonly, the attitude is, of course you’re depressed, you have a serious illness. This study shows that patients should have hope that they can be helped,” said study author Matthew Menza, MD, a Professor of Psychiatry and Neurology with UMDNJ-Robert Wood Johnson Medical School in Piscataway, NJ. “Second, the study suggests that we may need to use medications that affect both serotonin and norepinephrine, not just serotonin, in the brain to be successful in treating depression related to Parkinson’s disease.”
Menza also says that in addition to the older antidepressant, nortriptyline, that was tested in the study, there are newer mediations that affect both serotonin and norepinephrinem, and these need to be tested.
Tricyclic antidepressants are one of the older classes of antidepressants and have been used since the 1950s. Tricyclics have an increased risk of overdose and death due to toxic effects on the heart and brain. “People on a tricyclic antidepressant should have their dosages monitored closely by their doctor,” said Menza.
http://www.aan.com/
--------------------------------------------------------------------------------------------
Related Posts:
The use of antidepressant medications by patients with fibromyalgia syndrome is associated with a reduction in pain, sleep disturbances and depressed mood and improvement of health-related quality of life, according to an analysis of previous studies, which is published in the January 14 issue of JAMA. Fibromyalgia syndrome (FMS), which consists of chronic widespread pain
Full Post: Antidepressants improve symptoms of fibromyalgia
The first melatonergic antidepressant - Valdoxan/Thymanax (agomelatine) - has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients with major depressive disorder (MDD). Upon approval by the European Commission in early 2009, Valdoxan is expected to be
Full Post: Valdoxan - a melatonergic antidepressant - receives positive European opinion for major depressive disorder
A new study has revealed the most commonly prescribed medication for Australian women is antidepressants. The study, by researchers from Australian Longitudinal Study on Women’s Health (ALSWH). Pharmaceutical Benefits Scheme and Medicare data were linked to survey data to examine claims and costs of medications and other health care resources. University of Newcastle study co-director
Full Post: Antidepressants most common medicine for Australian women
Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of
Full Post: Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company’s novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA). The action date under the Prescription Drug User
Full Post: FDA accepts Labopharm’s NDA for formulation of trazodone --------------------------------------------------------------------------------------------
